Wyeth third quarter
This article was originally published in The Tan Sheet
Executive SummaryWyeth Consumer Healthcare's recent divestiture of theSolgar supplement business contributed to a 4.7% dip in domestic revenues for the third quarter, the firm reported during an earnings call Oct. 21.Wyeth closed the sale of its Solgar business to NBTY for $115 mil. on Aug. 1. Domestic sales for the division during the quarter closed at $382.5 mil., down from $401.5 mil. during the third quarter of 2004. Losses due to Solgar were partially offset by gains in worldwide Centrum revenues, up 14% to $150 mil. for the third quarter, the company said. Growth during the first nine months for the division was driven by a global increase in Robitussin, Caltrate and Advil sales. When excluding the impact of foreign exchange, total worldwide consumer net revenue decreased by 4% for the third quarter, Wyeth stated...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.